Modelled CKD Benefits of Broad Sodium-Glucose Cotransporter-2 Inhibitor Eligibility in the UK
Navdeep Tangri, Stacey Priest, Anthony Zara, Bo Ren Long, Naveen Rao, Clélia-Elsa Froguel, Fiona Adshead, Steven Chadban · 2026
Read Modelled CKD Benefits of Broad Sodium-Glucose Cotransporter-2 Inhibitor Eligibility in the UK by Navdeep Tangri, Stacey Priest, Anthony Zara, Bo Ren Long, Naveen Rao, Clélia-Elsa Froguel, Fiona Adshead, Steven Chadban (2026) in the Tower of Babel, a free online library of public-domain works preserved in clean, searchable text. No sign-up. The full text is served as a plain-text file at a predictable URL, where text is present: https://antarctic-labs.com/tower-of-babel/pmc-13273866.txt.
Description
Tangri and co-authors model wider SGLT-2 inhibitor access for UK kidney disease. Chronic kidney disease hits over ten percent of UK adults. These drugs slow kidney decline but are underused. Testing rules and guideline gaps block wider use. Five access scenarios were modeled over ten years from 2025.
The IMPACT CKD model simulated patients one by one. Tighter rules raised dialysis rates by 4 point 0 to 17 point 2 percent. Death rates rose 1 point 3 to 4 point 3 percent under tighter rules. Kidney care costs rose as access narrowed. The authors back the widest access case modeled.
Catalog record
| CREATOR | Navdeep Tangri, Stacey Priest, Anthony Zara, Bo Ren Long, Naveen Rao, Clélia-Elsa Froguel, Fiona Adshead, Steven Chadban |
|---|---|
| YEAR | 2026 |
| COLLECTION | PAPERS |
| FORMAT | TXT |
| FILE SIZE | 41 KB |
| VERSION | 1.0 |
| LICENSE | CC BY 4.0 |
| RIGHTS | CC BY |
| SOURCE | Europe PMC |